Phase II, Single Arm, Open Label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Latest Information Update: 03 Oct 2021
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Pharmacodynamics
- Sponsors Takeda
Most Recent Events
- 15 Oct 2019 Results published in the Journal of Infectious Diseases.
- 09 Feb 2017 New trial record